Research

Mixed

GLP-1 receptor agonist therapy induces lean mass loss proportional to fat loss (approx. 25% of total weight loss), which is a physiological response to caloric restriction rather than a unique pathological catabolic effect of the drug.

If you are taking a GLP-1 drug like Semaglutide, expect to lose about 25% of your total weight as muscle. This is normal and similar to losing weight through diet alone. To protect your muscle, prioritize resistance training and eat 1.2-1.6g of protein per kg of body weight daily.

GoodQualifiesHIGH confidence
Clinical trial evidence consistently shows that GLP-1RA therapy results in significant reductions in fat mass, accompanied by smaller but measurable decreases in lean mass... lean mass typically accounts for about one-quarter of total weight lost, this pattern is comparable to other weight-loss approaches and not uniquely harmful.
Giada Rossi et al. · Acta Diabetologica · 2025

Why this rating

Based on multiple RCTs (STEP 1, SURMOUNT) and meta-analyses cited in the review.

Source

Muscle loss and GLP-1R agonists use

Giada Rossi et al. · Acta Diabetologica · 2025

DOI 10.1007/s00592-025-02611-2

narrative_reviewCited 3×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →